Research is shedding light on the complex and powerful connection between bile acid and the farnesoid X receptor (FXR). Understand the metabolic effects of FXR.
Intercept is exploring FXR agonism and its effects throughout the body. Find out more about where our research is leading us.
Intercept supports independent, unsolicited research related to progressive non-viral liver diseases. Submit a proposal for consideration.
Intercept is expanding its pipeline to feature new indications for liver diseases with limited therapeutic options. Take a look at the direction we are going.
Intercept is focused on developing our lead compound, obeticholic acid, but we are also looking into the future with 2 novel compounds.
View scientific presentations for detailed clinical information about Intercept’s proprietary bile acid chemistry.